Search | Clinical Trials Finder

Conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Major Depression With Psychotic Features, Bipolar Disorder With Psychotic Features
Interventions: Coordinated Specialty Care (CSC); Other
Lead sponsor: Indiana University; Other
Eligibility: 16 Years to 35 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 6
States / cities: Indianapolis, Indiana • New Orleans, Louisiana • Ann Arbor, Michigan + 3 more

Conditions: Major Depressive Disorder, Psychotic Disorders
Interventions: ORG 34517; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: New York, New York

Conditions: Affective Disorders
Interventions: Ziprasidone, Sertraline, Haloperidol; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Major Depressive Disorder, Psychotic Disorders
Interventions: Mifepristone, matching placebo; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 257 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 23
States / cities: Pico Rivera, California • Riverside, California • San Diego, California + 20 more

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression With Psychotic Features
Interventions: Ending Self Stigma (ESS), Health and Wellness Group; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Perry Point, Maryland

Conditions: Psychosis, Schizophrenia Disorder, Schizoaffective Disorder, Major Depressive Disorder With Psychotic Features, Bipolar Disorder With Psychotic Features, Psychosis NOS, Schizophreniform Disorder, Psychotic Disorder, Cognition
Interventions: Modafinil, D-serine solution, Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 35 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Major Depressive Disorder Without Psychotic Features
Interventions: Asenapine 5-20 mg daily, Placebo 1-4 tablets daily; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 5
States / cities: Augusta, Georgia • Durham, North Carolina • Greenville, North Carolina + 1 more

Conditions: Schizophreniform Disorder, Schizoaffective Disorder, Psychosis, Depressive Disorder, Major, Bipolar Disorder
Interventions: Ziprasidone; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 13 Years to 17 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Depressive Disorder
Interventions: Duloxetine Hydrochloride; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Schizophrenia, Schizoaffective Disorder, Depressive Disorder, Major, Bipolar Disorder
Interventions: olanzapine versus risperidone; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Depressive Disorder, Major
Interventions: Mifepristone; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 13
States / cities: San Diego, California • Atlanta, Georgia • Las Vegas, Nevada + 10 more

Conditions: Schizophrenia, Schizoaffective Disorder, Delusional Disorder, Major Depressive Disorder With Psychotic Features
Interventions: Collaborative Decision Skills Training, Leveling Up; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: San Diego, California

Conditions: Major Depression With Psychotic Features
Interventions: risperidone; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Schizophrenia, Bipolar Disorder, Healthy, Psychosis, Schizophreniform Disorders, Schizo Affective Disorder, Major Depression With Psychotic Features
Interventions: Placebo and fMRI, Lorazepam and fMRI; Other · Drug
Lead sponsor: University of Michigan; Other
Eligibility: 16 Years to 60 Years
Enrollment: 143 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Major Depressive Disorder, Psychotic Disorders
Interventions: mifepristone, mifepristone matched placebo, mifepristone 600 mg, mifepristone 1200 mg; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 44
States / cities: Little Rock, Arkansas • Cerritos, California • Fountain Valley, California + 40 more

Conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychosis NOS, Autistic Disorder, Asperger Syndrome, Child Development Disorders, Pervasive, Bipolar I Disorder, Bipolar II Disorder, Mood Disorder NOS, Severe Major Depression With Psychotic Features, Single Episode Major Depression Without Psychotic Symptoms, Severe Mood Disorder With Psychotic Features
Interventions: Latuda©; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 6 Years to 19 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar Disorder, Severe Major Depression With Psychotic Features
Interventions: Naltrexone, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Depression, Psychotic Disorders, Depressive Disorder, Major
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Stanford, California

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder With Psychotic Features, Major Depression With Psychotic Features, Psychosis Not Otherwise Specified (NOS)
Interventions: Not listed
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Schizoaffective Disorders, Bipolar Disorder With Psychotic Features, Schizophrenia Disorders, Major Depressive Disorder With Psychotic Features, Psychosis NOS
Interventions: Transition Care Team; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 40 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Chicago, Illinois • Harvey, Illinois

Conditions: Major Depression With Psychotic Features
Interventions: quetiapine; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Major Depressive Disorder With Psychotic Features
Interventions: Olanzapine, Sertraline, placebo; Drug · Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 3
States / cities: Worcester, Massachusetts • New York, New York • Pittsburgh, Pennsylvania

Conditions: Major Depressive Disorder With Psychotic Features
Interventions: Quetiapine, escitalopram, Sertraline, Citalopram; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Schizophrenia, Bipolar Disorder, Depression, Psychotic Disorders
Interventions: aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine, Psychoeducational multifamily group treatment, Supported employment and education; Drug · Behavioral
Lead sponsor: MaineHealth; Other
Eligibility: 12 Years to 25 Years
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 6
States / cities: Sacramento, California • Portland, Maine • Ann Arbor, Michigan + 3 more

Search by objective public record fields.

Academic-Community EPINET (AC-EPINET)

Safety Study of ORG 34517 for Major Depression With Psychotic Features

Ziprasidone vs. Sertraline/Haloperidol in Psychotic Depression

A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression

Reducing Internalized Stigma in People With Serious Mental Illness

Cognitive Strategies in Early Psychosis 2

Antidepressant Plus Asenapine Versus Antidepressant Plus Placebo for Depression

Open-label Ziprasidone Study for Psychosis Treatment in Adolescents

Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder

Effects of Risperidone and Olanzapine on Patients With Schizophrenia, Schizoaffective Disorder, Major Depression or Bipolar Disorder

A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression

Adapting and Examining Collaborative Decision Skills Training Among Veterans With Serious Mental Illness

Treatment of Major Depressive Disorder With Psychotic Features.

Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis

A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression

Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents

Naltrexone for Antipsychotic-Induced Weight Gain

Clinical and Biological Characteristics of Psychotic Depression

Social Cognition in Longstanding Psychosis

Transition Care for FEP

Treatment of Depression With Quetiapine

Study of Pharmacotherapy of Psychotic Depression

Seroquel Alone Versus Seroquel With an SSRI for Depression With Psychotic Symptoms

Early Detection and Intervention for the Prevention of Psychosis